Emerging Company Profile: Former Sanofi-Genzyme exec David Meeker signed on to lead the startup, which is using a CRISPR-based drug discovery platform to develop specifically targeted therapies, with an initial focus on oncology and immunology, after leaving big pharma.
KSQ Therapeutics hopes to reduce the time and costs associated with drug development with its proprietary platform for developing targeted therapies, and it has raised $76m and recruited former Sanofi-Genzyme executive David Meeker as its CEO to build a portfolio of drug candidates.
Cambridge, Mass
Several genetic markers have been identified as attractive, novel drug targets, so the company will use its cash raised through Series A and B venture capital financings to
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
Vyepti revenues rise by nearly 70% in the first quarter.
